With Philips InCourage vest therapy and RespirTech’s support program
 
Your patients with bronchiectasis are

Living, breathing proof

Test your knowledge – is it COPD or bronchiectasis?

Bill
I’ve had the InCourage system for about nine months, and it has really been a game changer for me."

- Bill

Note: RespirTech stock photo, patient not pictured.

A powerful pairing

Philips InCourage vest therapy + RespirTech’s support program

 

Philips InCourage vest therapy helps patients who have conditions that challenge their respiratory health, like bronchiectasis, COPD, cystic fibrosis, and other pulmonary disorders that can be caused by neuromuscular or neuromotor conditions.

Mucus thumb
Research has shown that the triangle waveform technology of the Philips InCourage system aids in clearing up to 20% more mucus than competing technology.8,9
Helping Lung
RespirTech’s services are designed to create life-changing outcomes that last. Through encouraging and satisfying experiences, patients are more likely to achieve success.

Powerful results – proven to make a difference


No other vest therapy has a peer-reviewed outcomes study derived from the largest non-CF bronchiectasis registry in the world with nearly 18,000 patients.10
Up arrow 63%

64%

Improved airway clearance (rated “good to excellent”)*

Up arrow 45%

46%

Improved respiratory health (rated “good to excellent”)*

Down arrow 62%

61%

Reduced annual hospitalizations*

Down arrow 13%

13%

Decreased antibiotic use*

*Patient-reported results after 12 months with Philips InCourage vest therapy supported by the RespirTech outcomes program.10,11

Personal, ongoing attention
We can help see your patients through to success by:

Educating
A patient service advocate is assigned to each patient within 24 hours after therapy is prescribed to support the patient and work with your office to obtain necessary paperwork. Our compassionate team of clinical trainers helps your patients get started with therapy and answer any questions they may have.
 

†In a survey of 4,653 RespirTech patients.11
92 Percent

Of patients were satisfied/very satisfied with their overall customer experience.† 

93 Percent

Of patients said the product training was easy to understand.† 

Empowering
Our clinical educators, licensed respiratory therapists (RTs) and registered nurses (RNs), frequently reach out to patients, supporting them in the critical first month of treatment. This important touchpoint helps identify potential issues patients may experience, enabling our team to collaborate with yours to proactively address them.

Encouraging
For patients with bronchiectasis or COPD, our outcomes program is ongoing for up to two years, enabling us to keep track of their health and progress.

Proof is at your fingertips

Patient-specific reports
Personalized outcomes reports enable you to stay informed with how each patient is responding to InCourage vest therapy. You can gain valuable insights for adjusting vest prescription protocols and encouraging adherence.

Monthly aggregate reports
Monthly aggregate reports are available once you have a group of 10 or more patients on InCourage vest therapy.

Patient-specific and Monthly aggregate reports

Proof points


Hear from others about Philips InCourage vest therapy and RespirTech’s support program.
Proof points

When my patients ask if their quality of life can improve, I tell them yes."

 

- Frederic D. Seifer, MD, Pulmonologist‡

Dr. Eric Seifer is a paid consultant to RespirTech and a member of its advisory panel. Results  from case studies are not predictive of results in other cases. Results may vary.
Dr. Eric Seifer video

Evidence about the safety and efficacy of vest therapy is well-documented and continues to grow. Discover more proof.

Is it COPD or bronchiectasis?


Because COPD and bronchiectasis have many of the same symptoms, it can be difficult to identify the difference between them,1 especially when your patient may be experiencing symptoms of both.

See if you can correctly answer the following three questions.

25% of people living with serious COPD may have bronchiectasis. True or false?

True

False

The answer is false.

In truth, it’s estimated that 50% of people living with serious COPD may have bronchiectasis.2

Next question

The presence of bronchiectasis in patients with COPD is associated with more frequent and severe exacerbations. True or false?

True

False

The answer is true.

According to research, the presence of bronchiectasis in patients with COPD is associated with more frequent and severe exacerbations.3

Next question

Vest therapy has been shown to be effective for patients with COPD even when the status of bronchiectasis is unknown. True or false?

True

False

The answer is true.

Studies have found that vest therapy can be effective for non-CF bronchiectasis4 and also for COPD when the status of bronchiectasis  was unknown.5-7

View Summary

Want to hear more about how vest therapy and ongoing support can help your patients with bronchiectasis and/or COPD breathe easier?

**No matching rule found. Please select another answer

Need assistance? We’re happy to help.

Phone: 800.793.1261
Fax: 800.962.1611

Coverage criteria and prescription forms Download the forms below to reference coverage criteria and documentation requirements when prescribing Philips InCourage vest therapy.

References

1. Athanazio R. Airway disease: similarities and differences between asthma, COPD and bronchiectasis. Clinics (Sao Paulo). 2012;67(11):1335-1343.

2. Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823–831. 

3. Martínez-García M, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017;12:1401-1411. 

4. Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med. 2013;13:21.

5. Chakravorty I, Chahal K, Austin G. A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion. Int J Chron Obstruct Pulmon Dis. 2011;6:693-699.

6. Diette G, Bilderback A, Becker B, Kachel D, Wise R, Rand C. Adherence to high-frequency chest wall oscillation (HFCWO) improves quality of life in COPD [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16 2009. 2009:P2090.

7. Mahajan AK, Diette GB, Hatipoglu U, et al. High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial. Respir Res. 2011;12(1):120.

8. Milla CE, Hansen LG, Weber A, Warwick WJ. High-frequency chest compression: effect of the third generation compression waveform. Biomed Instrum Technol. 2004;38:322-328. Note: 8 CF patient study comparing triangular vs. sine waveform technology. 

9. Kempainen RR, Williams CB, Hazelwood A, Rubin BK, Milla CE. Comparison of high-frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. Chest. 2007;132(4):1227-1232.​
10. Methodology: Phone surveys at regular intervals with bronchiectasis patients using the InCourage system. Data collection began 10/01/2013. As of 05/31/2021, the total cohort was 23,213 patients; 21,049 patients completed the baseline survey; 13,303 patients in 1-month cohort; 9,569 in 6-month cohort; 7,720 in 12-month cohort​
11. RespirTech’s bronchiectasis patient outcomes program consists of follow-up calls at periodic intervals for up to two years to encourage HFCWO adherence and ensure the device is properly set for individual needs.​​
12. RespirTech customer care survey results 2015-2017.ethodology: As of 3/31/2020, self-reported data from nearly 18,000 bronchiectasis patients. 

Respitech
5905 Nathan Lane North, Suite 200, Plymouth, MN 55442
©2021 Koninklijke Philips N.V. All rights reserved.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.